Clinical trial

Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Metastatic Choroidal Melanoma

NCT01334008

Name

IC 2010-02

Description

Circulating tumor DNA detection and quantification in patients with metastatic choroidal melanoma.

Trial arms

Trial start

2011-04-01

Estimated PCD

2012-02-01

Trial end

2012-05-01

Status

Completed

Treatment

Blood sampling

30ml of patient peripherical blood will be collected

Arms:

Blood sampling

Size

Primary endpoint

Assessment and development of circulating tumor DNA detection techniques

2 years

Eligibility criteria

Inclusion Criteria: * Age \> or = 18 years. * Patient with a metastatic choroidal melanoma. * Patient with tumor or metastasis available for GNAQ (Guanine nucleotide blinding protein) status characterization. * Patient able to stand a blood collection. * Signed written informed consent approved by competent authority and ethic committee. Exclusion Criteria: * Patient without social protection/insurance. * Current pregnancy and lactation. * All social, medical, psychological, situations making the study impossible. * Person deprived of liberty.

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ACTUAL'}}

Updated at

2024-01-31

1 organization

1 product

2 indications

Organization

Product

Indication

Indication